Newron Pharmaceuticals, in association with its partners Zambon and US WorldMeds, has resubmitted the U.S. New Drug Application in September seeking a complete Class 2 response by the U.S. Food and Drug Administration for Xadago, also known by its generic name, safinamide. Read More »

Amgen's Phase 3 clinical trial to assess XGEVA compared to zoledronic acid has achieved its primary goal of proving to delay the time to the first skeletal-related event on-study for multiple myeloma patients. Read More »

Medicaid could see $51.1 billion over the next decade if a “full range of pharmacy benefit management tools” is employed, according to a new report completed by The Menges Group and released by the Pharmaceutical Care Management Association (PCMA). Read More »